Cover Image
市場調查報告書

中國的體外診斷劑產業的調查與預測

Research and Forecast of China IVD Reagent (In Vitro Diagnostic Reagent) Industry, 2014-2018

出版商 Huidian Research 商品編碼 278310
出版日期 內容資訊 英文 90 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的體外診斷劑產業的調查與預測 Research and Forecast of China IVD Reagent (In Vitro Diagnostic Reagent) Industry, 2014-2018
出版日期: 2014年02月20日 內容資訊: 英文 90 Pages
簡介

中國體外診斷歷史尚淺,目前其發展呈現落後於歐美的狀態。根據體外診斷試劑特別委員會所提供的資料指出,國內相關廠商有300∼400家。其中具有規定以上標準的有200家,另一方面,具有一年銷售額1億人民幣以上規模的企業僅20家。企業多為小規模,且產品種類也不多。2013年國內體外診斷市場的整體規模達到225人民幣,其中體外診斷試劑約佔163億人民幣。

本報告以中國體外診斷劑產業為焦點,提供其外部環境和市場活動、進出口、競爭情形等,各方面的最新市場資訊,為您概述為以下內容。

第1章 體外診斷劑產業概要

  • 定義與分類
    • 生物製藥的定義與分類
    • 體外診斷劑的定義與分類
  • 發展史
  • 產業鏈
  • 主要領域概要
    • 生物化學診斷劑產業
    • 免疫診斷試劑
    • 分子診斷試劑

第2章 中國體外診斷劑產業的運作環境

  • 全球體外診斷劑產業的發展概況
  • 中國生物醫藥品產業的發展概況
  • 相關產業的營運與政策
    • 產業統籌政府機關
    • 產業指導體制
    • 主要的法規及法規
    • 主要產業政策

第3章 中國體外診斷劑市場運作情形

  • 發展情形
  • 需求
    • 市場整體需求
    • 主要產品發展趨勢
  • 競爭環境
  • 進入障礙
    • 技術的障礙
    • 品質、品牌的障礙
    • 行銷流通管道的障礙
    • 市場進入的障礙
  • 利益水準與趨勢變化
  • 產業發展的阻礙係數
    • 市場集中率低,嚴重的產品均一性
    • 相對低水準的整體研究開發投資
    • 外資大企業佔有國內高級市場
  • 技術水準與經營模式
    • 技術水準與開發趨勢
    • 經營模式的特徵
  • 週期性、地區特性、季節性
    • 週期性
    • 地區特性
    • 季節性

第4章 中國體外診斷劑產業的進出口

  • 進口
  • 出口

第5章 中國體外診斷劑產業的主要企業(企業簡介,產業,主要的競爭力,研究開發企劃及產業計畫等)

  • Shanghai Kehua Bio-engineering Co., Ltd.
  • DAAN Gene Co., Ltd.
  • Shanghai Fosun Pharmaceutical (Group) CO., Ltd.
  • BioSino Bio-technology and Science Inc.
  • Beijing Leadman Biochemistry Co., Ltd.
  • Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
  • Mindray
  • Zhejiang DIAN Diagnosis Co., Ltd. (DIAN Diagnosis)

第6章 中國體外診斷劑產業的未來發展

  • 發展趨勢
  • 機會
  • 市場規模擴大的預測

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Research and Forecast of China IVD Reagent (In Vitro Diagnostic Reagent) Industry, 2014-2018 mainly conducts in-depth analysis on the external environment, market operation, import & export of China's IVD reagent industry, and also summaries the latest development of key Chinese domestic enterprises in 2013, and finally forecasts the future industrial development. The information can offer investors the decisive reference for their investment in the field.

IVD reagent industry is an emerging industry in China, the start is late and the development is relatively backward compares with occidental countries. According to the data provided by IVD Special Committee, there are 300 to 400 IVD reagent manufacturing enterprises in China, of which, 200 enterprises own above designated scale. However, only about 20 enterprises have the ability to achieve annual sales income of more than CNY 100 million; most of enterprises are in small scale and the product variety is few.

In 2013, the market scale of China's IVD industry reached CNY 22.5 billion; among them, the market scale of IVD reagents was about CNY 16.3 billion.

The state policy encourages the competitive enterprises to strengthen their strength. In 2013, a series of policies which target to improve industry standard and threshold entered the substantive operation stage, which accelerates the elimination of small enterprises and improves the industry concentration ratio. Industrial consolidation is the development trend, and the enterprises with capital, technology and scale advantages will win gradually.

In recent years, due to the continued sluggishness of European and American pharmaceutical market, the international giants target on the market expansion brought by China's new medical reform, and entered China's market in succession; after the China-oriented R&D center transfer, these powerful enterprises began to compete with China's enterprises in the low and medium-end markets through mergers, acquisitions, capital increase and production expansion; therefore, the competitive enterprises in China's diagnostic reagent subdivided industries will face more sever competitions.

Table of Contents

1. Overview of Diagnostic Reagent Industry

  • 1.1. Definition and Classification
    • 1.1.1. Definition and Classification of Biological Products
    • 1.1.2. Definition and Classification of IVD Reagents
  • 1.2. Development History
  • 1.3. Industry Chain
  • 1.4. Overview of Main Sub-industries
    • 1.4.1. Biochemical Diagnostic Reagent Industry
    • 1.4.2. Immune Diagnostic Reagent Industry
    • 1.4.3. Molecular Diagnostic Reagent Industry

2. Operating Environment of China's IVD Reagent Industry

  • 2.1. Development Overview of Global IVD Reagent Industry
  • 2.2. Development Overview of China's Bio-pharmaceutical Industry
  • 2.3. National Related Industry Management and Policy
    • 2.3.1. Industry Competent Departments
    • 2.3.2. Industry Supervision System
    • 2.3.3. Main Laws and Regulations
    • 2.3.4. Main Industry Policies

3. Operation State of China's IVD Reagent Market

  • 3.1. Development Status
  • 3.2. Demand
    • 3.2.1. Overall Market Demand
    • 3.2.2. Application Status and Development Trend of Main Varieties
  • 3.3. Competitive Pattern
  • 3.4. Barriers to Entry
    • 3.4.1. Technology Barrier
    • 3.4.2. Quality and Brand Barrier
    • 3.4.3. Marketing Channel Barrier
    • 3.4.4. Market Access Barrier
  • 3.5. Profit Level and Variation Trend
  • 3.6. Adverse Factors for the Industry Development
    • 3.6.1. Low Market Concentration Ratio; Serious Product Homogeneity
    • 3.6.2. Relatively Low Overall R&D Investment Level
    • 3.6.3. International Giants Occupying Dominant Positions in China's High-end Market
  • 3.7. Technological Level and Business Model
    • 3.7.1. Technological Level and Development Trend
    • 3.7.2. Characteristics of Business Model
  • 3.8. Periodical, Regional and Seasonal Characteristics
    • 3.8.1. Periodicity
    • 3.8.2. Regional Nature
    • 3.8.3. Seasonality
  • 3.9. Relevance and Influence of Upstream Industries and Downstream Industries to the IVD Reagent Industry
    • 3.9.1. Upstream Raw Materials Mainly Depending on Imports
    • 3.9.2. Downstream Demands Showing the Rigidity
    • 3.9.3. Relevance with the IVD Instrument Industry

4. Import and Export of China's IVD Reagent Industry

  • 4.1. Import
  • 4.2. Export

5. China's Key IVD Reagent Enterprises

  • 5.1. Shanghai Kehua Bio-engineering Co., Ltd.
    • 5.1.1. Company Profile
    • 5.1.2. Operating Conditions
    • 5.1.3. Core Competitiveness
    • 5.1.4. R & D Project, Business Plan and Future Development Strategy, 2013
  • 5.2. DAAN Gene Co., Ltd.
    • 5.2.1. Company Profile
    • 5.2.2. Business Development
    • 5.2.3. Main Business Composition
    • 5.2.4. Core Competitiveness
    • 5.2.5. Acquiring the Official Approval of Ministry of Finance, Equity Incentive Plan Getting Great Progress
  • 5.3. Shanghai Fosun Pharmaceutical (Group) CO., Ltd.
    • 5.3.1. Company Profile
    • 5.3.2. Main Business Composition
    • 5.3.3. Development of Medical Diagnosis and Medical Device Business
  • 5.4. BioSino Bio-technology and Science Inc.
    • 5.4.1. Company Profile
    • 5.4.2. Operating Conditions
    • 5.4.3. Future Development Strategy
  • 5.5. Beijing Leadman Biochemistry Co., Ltd.
    • 5.5.1. Company Profile
    • 5.5.2. Operating Conditions
    • 5.5.3. Main Business Composition
  • 5.6. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
    • 5.6.1. Company Profile
    • 5.6.2. Operating Conditions
    • 5.6.3. Products
  • 5.7. Mindray
    • 5.7.1. Company Profile
    • 5.7.2. Operating Conditions
    • 5.7.3. Business Development
  • 5.8. Zhejiang DIAN Diagnosis Co., Ltd. (DIAN Diagnosis)
    • 5.8.1. Company Profile
    • 5.8.2. Business Development
    • 5.8.3. Main Business Composition

6. Future Development of China's IVD Reagent Industry

  • 6.1. Development Trends
  • 6.2. Opportunities
  • 6.3. Growth Forecast of Market Scale, 2014-2018
Back to Top